rs1043246 - ATP2A3
Magnitude 2.2 · 3 studies on file
Reported associations
-
Genetic drivers of heterogeneity in type 2 diabetes pathophysiology - Unknown journal (n.d.) · Unknown authors · PubMed 38374256
ABSTRACT: Type 2 diabetes (T2D) is a heterogeneous disease that develops through diverse pathophysiological processes and molecular mechanisms that are often specific to cell type. Here, to characterize the genetic contribution to these processes across ancestry groups, we aggregate genome-wide association study data from 2,535,601 individuals (39.7% not of European ancestry), including 428,452 cases of T2D. We identify 1,289 independent association signals at genome-wide significance (P < 5 × 10−8) that map to 611 loci, of which 145 loci are, to our knowledge, previously unreported. We define eight non-overlapping clusters of T2D signals that are characterized by distinct profiles of cardiometabolic trait associations. These clusters are differentially enriched for cell-type-sp
-
Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation - Unknown journal (n.d.) · Unknown authors · PubMed 35551307
ABSTRACT: We assembled an ancestrally diverse collection of genome-wide association studies (GWAS) of type 2 diabetes (T2D) in 180,834 cases and 1,159,055 controls (48.9% non-European descent) through the DIAMANTE (DIAbetes Meta-ANalysis of Trans-Ethnic association studies) Consortium. Multi-ancestry GWAS meta-analysis identified 237 loci attaining stringent genome-wide significance (P < 5 x 10−9), which were delineated to 338 distinct association signals. Fine-mapping of these signals was enhanced by the increased sample size and expanded population diversity of the multi-ancestry meta-analysis, which localized 54.4% of T2D associations to a single variant with >50% posterior probability. This improved fine-mapping enabled systematic assessment of candidate causal genes and molecular me
-
Fine-mapping of an expanded set of type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps - Unknown journal (n.d.) · Unknown authors · PubMed 30297969
ABSTRACT: We aggregated genome-wide genotyping data from 32 European-descent GWAS (74,124 T2D cases, 824,006 controls) imputed to high-density reference panels of >30,000 sequenced haplotypes. Analysis of ˜27M variants (˜21M with minor allele frequency [MAF]<5%), identified 243 genome-wide significant loci (p<5x10-8; MAF 0.02%-50%; odds ratio [OR] 1.04-8.05), 135 not previously-implicated in T2D-predisposition. Conditional analyses revealed 160 additional distinct association signals (p<10-5) within the identified loci. The combined set of 403 T2D-risk signals includes 56 low-frequency (0.5%≤MAF<5%) and 24 rare (MAF<0.5%) index SNPs at 60 loci, including 14 with estimated allelic OR>2. Forty-one of the signals displayed effect-size heterogeneity between BMI-unadjusted and adjusted anal
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Diet
-
emphasize low glycemic index carbohydrates Moderate
rs1043246-G increases type 2 diabetes risk through impaired glucose handling. Lower glycemic load reduces postprandial glucose spikes and diabetes progression.
prioritize whole grains, legumes, non-starchy vegetables; limit refined grains and sugary foods
Lifestyle
-
regular physical activity Moderate
rs1043246-G carriers are at higher type 2 diabetes risk. Aerobic exercise improves insulin sensitivity and glucose clearance, primary interventions for risk reduction.
150 minutes moderate-intensity weekly aerobic activity, or equivalent resistance training
Screening
-
type 2 diabetes screening High
rs1043246-G carriers have significantly increased type 2 diabetes risk (OR=1.050 per allele across multiple large cohorts). Early glucose monitoring detects impaired fasting glucose and prediabetes.
baseline HbA1c and fasting glucose at age 30-35, then every 1-2 years